| Primary | Percentage of Participants With Complete Aneurysm Occlusion (RCAO) Without Retreatment at 12-Month Post Procedure | The Raymond-Roy Grading scale used for judging intracranial aneurysm (IA) endosaccular embolization success ranges from Grade I to III where, Grade I is completion occlusion with no flow of contrast seen in the aneurysm sac, Grade II is partial occlusion with some flow or eddy flow in the aneurysm sac and Grade III is residual aneurysm or Incomplete occlusion with apparent flow in the aneurysm sac. RCAO was assessed by the Independent Core Laboratory, complete aneurysm occlusion is defined as an aneurysm in which a Grade I (completion occlusion), is achieved on the Raymond Scale at the relevant post-procedure angiogram, without additional procedures for treatment of the aneurysm since the index procedure. Participants who were retreated (retreatment includes staged procedures) prior to the 12-month were considered not to have achieved complete aneurysm occlusion. | Modified Intent to Treat (mITT) analysis set: participants who were found to be eligible for treatment of ENTEPRISE during pre-procedure angiographic assessment, and in whom treatment is attempted. Here 'N' (Number of participants analyzed) included all participants available at 12-month visit with non missing values for this outcome measure (OM). | Posted | | Number | 95% Confidence Interval | Percentage of Participants | | 12 Months Post Procedure | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Percentage of Participants With Major Ipsilateral Stroke and/or Death Due to Ipsilateral Stroke at 12 Months Post Procedure | The incidence of a major ipsilateral stroke and/or death due to ipsilateral stroke was evaluated from the start of the index procedure until completion of the 12-month follow-up. A major ipsilateral stroke is defined as a new neurological event which is ipsilateral and in the vascular distribution territory of the stenting procedure and that results in an increase of greater than or equal to (>=) 4 on the National Institute of Health Stroke Scale (NIHSS) as compared to baseline and persists for greater than 24 hours. The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of 0 indicates no stroke; 1-4 as minor stroke; 5-15 as moderate stroke; 15-20 as moderate/severe stroke; 21-42 as severe stroke. NIHSS worsening is defined as an increase from baseline of >= 4. | mITT analysis set defined as participants who were found to be eligible for treatment of ENTEPRISE during pre-procedure angiographic assessment, and in whom treatment is attempted. Here 'N' (Number of participants analyzed) signifies participants who have been followed-up to the timepoint of interest (12 months) in the population for this OM. | Posted | | Number | 95% Confidence Interval | Percentage of participants | | At 12 Months Post Procedure | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
|
| Primary | Percentage of Participant With In-Stent Stenosis at 12 Months Post Procedure Per Independent Core Laboratory | In-stent stenosis is defined as greater than 50 percent (%) narrowing of the vessel within the ENTERPRISE stent or within 10 millimeters (mm) of either end of the stent. | mITT analysis set is defined as participants who were found to be eligible for treatment of ENTEPRISE during pre-procedure angiographic assessment, and in whom treatment is attempted. Here 'N' (Number of participants analyzed) signifies all participants who were available at the 12-month visit with non-missing values for this OM. | Posted | | Number | 95% Confidence Interval | Percentage of participants | | At 12 Months post procedure | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants With Procedure Success Immediately Post-procedure (Acute), 6 and 12 Months | The procedure success rate is defined to be the percentage of aneurysms in which coil mass position is maintained within the sac with parent artery patency, without additional procedures for treatment of the aneurysm since the index procedure. The procedure success was summarized immediately post-treatment (acute), and at the 6- and 12-month follow-up assessments. | mITT analysis set is defined as participants who were found to be eligible for treatment of ENTEPRISE during pre-procedure angiographic assessment, and in whom treatment is attempted. Here 'n' (number analyzed) signifies participants available at specified visits with non-missing values of the OM. | Posted | | Count of Participants | | Participants | | Immediately post-procedure (acute), 6 and 12 months | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants With Complete Aneurysm Occlusion as Per the Raymond Scale Immediately Post-procedure (Acute), 6 and 12 Months | The Raymond-Roy Grading scale used for judging intracranial aneurysm (IA) endosaccular embolization success ranges from Grade I to III where, Grade I is completion occlusion with no flow of contrast seen in the aneurysm sac, Grade II is partial occlusion with some flow or eddy flow in the aneurysm sac and Grade III is residual aneurysm or Incomplete occlusion with apparent flow in the aneurysm sac. RCAO was assessed by the Independent Core Laboratory, complete aneurysm occlusion is defined as an aneurysm in which a Grade I (completion occlusion), is achieved on the Raymond Scale at the relevant post-procedure angiogram, without additional procedures for treatment of the aneurysm since the index procedure. Participants who are retreated (retreatment includes staged procedures) prior to the 12-month were considered not to have achieved complete aneurysm occlusion. | mITT analysis set included. Here 'N' (Number of participants analyzed) signifies all evaluable participants with valid assessments post procedure for this OM and 'n' (number analyzed) signifies participants available at the schedule visits with non-missing values of the OM. | Posted | | Count of Participants | | Participants | | Immediately post-procedure (acute), 6 and 12 months | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
|
| Secondary | Number of Participants With Complete/Partial Aneurysm Occlusion as Per the Raymond Scale Immediately Post-procedure (Acute), 6 and 12 Months | The Raymond-Roy Grading scale used for judging intracranial aneurysm (IA) endosaccular embolization success ranges from Grade I to III where, Grade I is completion occlusion with no flow of contrast seen in the aneurysm sac, Grade II is partial occlusion with some flow or eddy flow in the aneurysm sac and Grade III is residual aneurysm or Incomplete occlusion with apparent flow in the aneurysm sac. Complete/partial aneurysm occlusion is defined as an aneurysm in which a score of 1 (complete occlusion) or 2 (residual neck) is achieved on the Raymond Scale, regardless of retreatment. Participants who are retreated (retreatment includes staged procedures) prior to the 12-month post-procedure follow-up visit was considered not to have achieved complete aneurysm occlusion. | mITT analysis set included. Here 'N' (Number of participants analyzed) signifies all evaluable participants with valid assessments post procedure for this OM and 'n' (number analyzed) signifies number of participants available at the specified visits with non-missing values of the OM. | Posted | | Count of Participants | | Participants | | Immediately post-procedure (acute), 6 and 12 Months | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
|
| Secondary | Number of Participants With 25% to 100% Aneurysm Occlusion Immediately Post-procedure (Acute), 6 and 12 Months | Number of Participants with aneurysms occlusion of 100%, 90%-99%, 70-89%, 50-69%, 25-49%, or <25% occlusion in accordance with Consensus Grades 0 (100% complete aneurysm occlusion) - 5 (<25% volumetric aneurysm occlusion), respectively, was reported immediately post-procedure (acute), and at the 6 and 12 month follow-up, respectively. | mITT analysis set included. Here 'N' (Number of participants analyzed) signifies all evaluable participants with valid assessments post procedure for this OM and 'n' (number analyzed) signifies number of participants available at the specified visits with non-missing values of the OM. | Posted | | Count of Participants | | Participants | | Immediately post-procedure (acute), 6 and 12 months | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants With Aneurysm Recanalization | Number of participants with aneurysm recanalization was reported. Recanalization was defined as an increase in aneurysm filling as compared to the previous study-specified angiographic assessment, resulting in a change in (that is, worsening of) the Raymond classification. | mITT analysis set is defined as participants who were found to be eligible for treatment of ENTEPRISE during pre-procedure angiographic assessment, and in whom treatment is attempted. Here 'N' (number of participants analyzed) included all evaluable participants with data available for this OM. | Posted | | Count of Participants | | Participants | | Up to 12 months | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants Retreated With Any Additional Treatment | Retreatment was defined as any additional treatment of the target aneurysm after the index procedure (retreatment includes staged procedures), or an additional procedure (regardless of whether retreatment is by surgery or endovascular treatment) due to recanalization, rupture or bleeding. | mITT analysis set: participants who were found to be eligible for treatment of ENTEPRISE during pre-procedure angiographic assessment, and in whom treatment is attempted. Here 'N' (number of participants analyzed) included participants who had been followed up to 12-month follow-up, or otherwise who were retreated prior to 12-Month Follow-up. | Posted | | Count of Participants | | Participants | | Up to 12 months | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants With New Neurological Deficits as Per the Modified Rankin Scale (mRS) Score | Observed scores on the Modified Ranking Scale was presented at baseline (pre-procedure) and follow-up (30 days, 6 and 12 months post-procedure). mRS score: 0 = no symptoms at all; 1 = no significant disability despite symptoms, able to carry out all usual duties and activities; 2 = slight disability, unable to carry out all previous activities but able to look after own affairs without assistant; 3 = moderate disability, requires some help, but able to walk without assistance; 4 = moderate to severe disability, unable to walk without assistance, and unable to attend own bodily needs without assistance; 5 = severe disability, bedridden, incontinent, and requiring constant nursing care and attention; 6 = dead. The number of participants who had an increase in mRS > 2 from baseline not related to stroke or death was also be presented for each follow-up time point. | mITT analysis set: participants who were found to be eligible for treatment of ENTEPRISE during pre-procedure angiographic assessment, and in whom treatment is attempted. Here 'n' (number analyzed) signifies number of participants available at the specified visits with non-missing values of the OM. | Posted | | Count of Participants | | Participants | | Post-procedure up to 30-Day, 6-Month Follow-up and 12-Month Follow-up | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
|
| Secondary | Number of Participants With NIH Stroke Scale (NIHSS) Worsening | The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The scores range from 0 to 42 with a score of 0 indicates no stroke; 1-4 as minor stroke; 5-15 as moderate stroke; 15-20 as moderate/severe stroke; 21-42 as severe stroke. NIHSS worsening is defined as an increase from baseline of >= 4. | mITT analysis set included. Here 'N' (Number of participants analyzed) included participants who had at least one post-baseline NIHSS scores and 'n' (number analyzed) signifies number of participants analyzed at specified time points. | Posted | | Count of Participants | | Participants | | Post-procedure up to 6-Month and 12-Month Follow-up | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants With Reduced Thrombolysis in Cerebral Infarction (TICI) Flow (New Occurrence of TICI Grade of 0 or 1) | The percentage of target aneurysms in which a new occurrence of unintentional and persistent reduced TICI flow (TICI grade of 0: No perfusion or 1: Partial perfusion) was observed at the target vessel during the index procedure as a result of a mechanical obstruction such as dissection or luminal thrombus was evaluated. TICI evaluates perfusion severity and ranges from Grade 0 (No perfusion) to 3 (Complete perfusion). | mITT analysis set is defined as participants who were found to be eligible for treatment of ENTEPRISE during pre-procedure angiographic assessment, and in whom treatment is attempted. | Posted | | Count of Participants | | Participants | | Day 1 (Intraoperative) | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants With Bleeding Complications | The number of participants who experienced a procedure-related hemorrhagic event which required any of the following was evaluated: blood transfusion, surgical intervention, a new hospitalization, or lengthening of hospital stay. The complications of hematoma requiring treatment (that is, hematoma > 5 centimeter [cm] in diameter occurring at the access site) and retroperitoneal bleeding were reported as hemorrhagic events. | mITT analysis set included. Here 'N' (Number of participants analyzed) included all participants with data available for this OM and 'n' (number analyzed) signifies number of participants analyzed at specified time points. | Posted | | Count of Participants | | Participants | | 12 months | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants With In-Stent Stenosis Per Independent Core Laboratory During Procedure (Acute), Post-procedure up to 6 Months and 12 Months Follow up | In-stent stenosis is defined as greater than 50% narrowing of the vessel within the ENTERPRISE stent or within 10 mm of either end of the stent. | mITT analysis set included. Here 'N' (Number of participants analyzed) included all participants with data available for this OM and 'n' (number analyzed) signifies number of participants analyzed at specified time points. | Posted | | Count of Participants | | Participants | | During procedure (acute), post-procedure up to 6 months and 12 months follow up | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |
| Secondary | Number of Participants With Thrombosis Per Independent Core Laboratory | Thrombosis is defined as in-stent thrombosis. | mITT analysis set included. Here 'N' (Number of participants analyzed) included all participants with data available for this OM and 'n' (number analyzed) signifies number of participants analyzed at specified time points. | Posted | | Count of Participants | | Participants | | During procedure (acute), post-procedure up to 6 months and 12 months follow up | | | | ID | Title | Description |
|---|
| OG000 | CODMAN ENTERPRISE | Participants with an unruptured wide-neck, intracranial saccular anterior circulation aneurysm (less than or equal to [<=] 10 millimeters [mm]), arising from a parent vessel with a diameter of greater than or equal to [>=] 2.5 mm and <= 4 mm, treated with either CODMAN ENTERPRISE Vascular Reconstruction Device and Delivery System (ENTERPRISE VRD system) and or CODMAN ENTERPRISE 2 Vascular Reconstruction Device and Delivery System (ENTERPRISE 2 VRD system). |
| |